Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR1459 DDI with Rifampicin in Healthy Volunteers
NCT04649723Phase 1Completed
- Sponsor
- Hengrui
- Start
- Nov 2020
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of edralbrutinib in B cell malignancies, primary membranous nephropathy (PMN) and neuromyelitis optica spectrum disorder (NMOSD), sponsored by Hengrui. Primary endpoints: Maximum Plasma Concentration at Day 9, Area Under the Plasma Concentration-time Curve from 0 to last quantifiable concentration at Day 9 and 1 more. Started Nov 2020; status: completed.
02
Drugs
edralbrutinib
03
Conditions
B cell malignanciesprimary membranous nephropathy (PMN)neuromyelitis optica spectrum disorder (NMOSD)
Beyond the preview
Go deeper on NCT04649723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04649723.